1. Biosimilars Versus Originators in Children With Juvenile Idiopathic Arthritis: A Real-World Experience.
- Author
-
Gicchino, Maria Francesca, Capasso, Giusy, Amodio, Alessia, Miraglia del Giudice, Emanuele, Olivieri, Alma Nunzia, and Di Sessa, Anna
- Abstract
We aimed to evaluate the efficacy, safety, and immunogenicity profile of Etanercept (ETA) and Adalimumab (ADA) biosimilars (BIOs) compared to their originators in children with juvenile idiopathic arthritis (JIA). Eighty-one JIA children treated with ETA or ADA originators or BIOs were examined at baseline (T0) and after 3- (T1), 6- (T2), 12- (T3), and 24-(T4) months after starting treatment. Lower Juvenile Arthritis Disease Activity Score 10 (JADAS-10) scores were reported at T1, T2, T3, and T4 in JIA children treated with BIOs than originators (all p < 0.05). At T1 and T3, anti-drugs antibodies levels were lower in children receiving BIOs than originators (p = 0.04 and p = 0.0007, respectively), even after adjustments (both p < 0.05). Relapses were lower for BIOs compared to originators (p < 0.001). Safety profile was comparable between the groups (p > 0.05). A better overall profile of BIOs than originators was demonstrated in JIA children, but larger confirmatory studies are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF